Sunyana Gadal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sunyana Gadal has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Neal Rosen
Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, USA
52 shared publications - Rona Yaeger
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
49 shared publications - Anurag Singh
Pfizer Boulder Research and Development, Boulder, Colorado. 11
37 shared publications - Arnab Kumar Maity
Pfizer Inc 10777 Science Center Drive 92121 San Diego CA USA
37 shared publications - Bhaswati Sengupta
Pfizer Boulder Research and Development, Boulder, Colorado. 11
37 shared publications - Brian R. Baer
Departments of Drug Metabolism and Pharmacokinetics, Pfizer Boulder R&D, Boulder, Colorado
37 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
Table S1. Cell lines used for cell-based pERK assays in Figure 1A
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
Table S1. Cell lines used for cell-based pERK assays in Figure 1A
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
Figure S3. Mouse plasma PK profiles for exarafenib and plixorafenib.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
Figure S3. Mouse plasma PK profiles for exarafenib and plixorafenib.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Video 1b from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with MEK inhibitor
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Video 1b from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with MEK inhibitor
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
Table S2. X-ray crystallography data collection and refinement statistics
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
Table S2. X-ray crystallography data collection and refinement statistics
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Video 1a from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with DMSO
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Video 1a from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Confocal Z-stack image of cells treated with DMSO
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
Figure S1. Preclinical characterization of PF-07799933 and comparison to other RAF inhibitors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
Figure S1. Preclinical characterization of PF-07799933 and comparison to other RAF inhibitors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video-2 from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Time-lapse video with and without ERK inhibition
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video-2 from Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration
Time-lapse video with and without ERK inhibition
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
Figure S2. Crystal structures of BRAF kinase domain with PF-07799933 or encorafenib.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
Figure S2. Crystal structures of BRAF kinase domain with PF-07799933 or encorafenib.